Sanjay Rathi, MD
Neurological Surgery · North Haven, CTNPI 1821007972
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $405,770 of the $540,826 with a category attached, or 75.0%. 56 manufacturers reported payments, led by AbbVie at 37.2% of the total. Among neurological surgery clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,277 payments — averaging $423.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$201K
- EMD Serono, Inc.$196K
- Neurocrine Biosciences, Inc.$64K
- Amneal Pharmaceuticals LLC$24K
- Axsome Therapeutics, Inc.$10K
- Kyowa Kirin, Inc.$8K
- plus $38K from 50 others
What the payments were for
- Consulting fees$40,8058%
- Speaking & faculty fees$405,77075%
- Travel & lodging$41,4128%
- Food & beverage$49,7649%
- Education$3,0761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$540,826 in reported general payments places this provider in the 95th percentile of 94 neurological surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 38 | $190,616 |
| IngrezzaValbenazine Tosylate | 14 | $119,875 |
| RytaryCarbidopa/Levodopa | 101 | $102,502 |
| BotoxOnabotulinumtoxina | 81 | $100,291 |
| GocovriAmantadine Hcl | 23 | $87,724 |
| NourianzIstradefylline | 24 | $81,086 |
| CopaxoneGlatiramer Acetate | 13 | $74,599 |
| OngentysOpicapone | 78 | $59,733 |
| UbrelvyUbrogepant | 19 | $41,991 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $18,548 |
| AptiomEslicarbazepine Acetate | 13 | $15,169 |
| QuviviqDaridorexant Hcl | 24 | $11,668 |
| Rasagiline Mesylate | 57 | $11,319 |
| Gabapentin | 33 | $1,169 |
| Quetiapine Fumarate | 52 | $1,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $224 | $190,61638 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $63,665 | $179,60892 claims |
| AbbVieBotox, Ubrelvy | $201,255 | $142,282100 claims |
| Amneal Pharmaceuticals LLCRytary | $23,997 | $102,502101 claims |
| MDD US Operations, LLCGocovri | $577 | $87,72423 claims |
| Kyowa Kirin, Inc.Nourianz | $7,720 | $81,08624 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $781 | $74,59913 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $125 | $15,16913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 94 neurological surgery providers in Connecticut.
Other neurological surgery in North Haven
- Murat GunelNew Haven$839K
- Patrick SenatusSouth Windsor$309K
- Ahmed KhanNew Britain$250K
- Abraham MintzShelton$204K
- Joshua MarcusDanbury$142K
- Pooia FattahiMiddlebury$140K
- Pedro de Oliveira CoutinhoNew Haven$129K
- Ehud MendelNew Haven$120K
- Charles MatoukNew Haven$114K
- Ryan HebertNew Haven$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.